Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

doi:10.1056/NEJM200104053441409

Volume 344:1084-1086		April 5, 2001		Number 14

Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Chronic myeloid leukemia (CML) is one of the most remarkablecancers.¹^,² It was probably the first type of leukemia to berecognized, in the 1840s, as a distinct entity. A landmark wasthe discovery of the Philadelphia (Ph) chromosome in 1960.³This led to the identification in CML cells of the BCR-ABL fusiongene and its corresponding protein, which is now firmly establishedas the unique cause of the initial, or "chronic," phase of CML.ABL and BCR, which are located on chromosomes 9 and 22, respectively,are normal genes whose function is still unknown. The ABL geneencodes a . . . [Full Text of this Article]

References

This article has been cited by other articles:

Hazarika, M., Jiang, X., Liu, Q., Lee, S.-L., Ramchandani, R., Garnett, C., Orr, M. S., Sridhara, R., Booth, B., Leighton, J. K., Timmer, W., Harapanhalli, R., Dagher, R., Justice, R., Pazdur, R. (2008). Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib. Clin. Cancer Res. 14: 5325-5331 [Abstract] [Full Text]
Croce, C. M. (2008). Oncogenes and Cancer. NEJM 358: 502-511 [Full Text]
Zhou, Y., Bouyer, P., Boron, W. F. (2006). Role of a tyrosine kinase in the CO2-induced stimulation of HCO3- reabsorption by rabbit S2 proximal tubules. Am. J. Physiol. Renal Physiol. 291: F358-F367 [Abstract] [Full Text]
Barnes, D. J., Palaiologou, D., Panousopoulou, E., Schultheis, B., Yong, A. S.M., Wong, A., Pattacini, L., Goldman, J. M., Melo, J. V. (2005). Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia. Cancer Res. 65: 8912-8919 [Abstract] [Full Text]
Chang, G., Orav, E. J., Tong, M.-Y., Antin, J. H. (2004). Predictors of 1-Year Survival Assessed at the Time of Bone Marrow Transplantation. Psychosomatics 45: 378-385 [Abstract] [Full Text]
Mikawa, M., Wang, H., Guo, L., Liu, R., Marik, J., Takada, Y., Lam, K., Lau, D. (2004). Novel peptide ligands for integrin {alpha}4{beta}1 overexpressed in cancer cells. Molecular Cancer Therapeutics 3: 1329-1334 [Abstract] [Full Text]
Guilhot, F. (2004). Indications for Imatinib Mesylate Therapy and Clinical Management. The Oncologist 9: 271-281 [Abstract] [Full Text]
Burman, K. D. (2004). A New Paradigm in the Treatment of Carcinoma: Specific Molecular Targeting. Endocrinology 145: 1027-1030 [Full Text]
Hamada, A., Miyano, H., Watanabe, H., Saito, H. (2003). Interaction of Imatinib Mesilate with Human P-Glycoprotein. J. Pharmacol. Exp. Ther. 307: 824-828 [Abstract] [Full Text]
Segura-Pacheco, B., Trejo-Becerril, C., Perez-Cardenas, E., Taja-Chayeb, L., Mariscal, I., Chavez, A., Acuna, C., Salazar, A. M., Lizano, M., Duenas-Gonzalez, A. (2003). Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy. Clin. Cancer Res. 9: 1596-1603 [Abstract] [Full Text]
Elmaagacli, A. H., Peceny, R., Steckel, N., Trenschel, R., Ottinger, H., Grosse-Wilde, H., Schaefer, U. W., Beelen, D. W. (2003). Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 101: 446-453 [Abstract] [Full Text]
Pathak, M. K., Dhawan, D., Lindner, D. J., Borden, E. C., Farver, C., Yi, T. (2002). Pentamidine Is an Inhibitor of PRL Phosphatases with Anticancer Activity. Molecular Cancer Therapeutics 1: 1255-1264 [Abstract] [Full Text]
Yi, T., Pathak, M. K., Lindner, D. J., Ketterer, M. E., Farver, C., Borden, E. C. (2002). Anticancer Activity of Sodium Stibogluconate in Synergy with IFNs. J. Immunol. 169: 5978-5985 [Abstract] [Full Text]
Luzzatto, L., Melo, J. V. (2002). Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. Blood 100: 1105-1106 [Full Text]
Cohen, M. H., Williams, G., Johnson, J. R., Duan, J., Gobburu, J., Rahman, A., Benson, K., Leighton, J., Kim, S. K., Wood, R., Rothmann, M., Chen, G., U, K. M., Staten, A. M., Pazdur, R. (2002). Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia. Clin. Cancer Res. 8: 935-942 [Abstract] [Full Text]
Kitiyakara, C., Atichartakarn, V. (2002). Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 17: 685-687 [Full Text]
Ramaswamy, S., Golub, T. R. (2002). DNA Microarrays in Clinical Oncology. JCO 20: 1932-1941 [Abstract] [Full Text]
O'Dwyer, M. (2002). Multifaceted Approach to the Treatment of Bcr-Abl-Positive Leukemias. The Oncologist 7: 30-38 [Abstract] [Full Text]
Hofmann, W.-K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., Koeffler, H. P. (2002). Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99: 1860-1862 [Abstract] [Full Text]
Savage, D. G., Antman, K. H. (2002). Imatinib Mesylate -- A New Oral Targeted Therapy. NEJM 346: 683-693 [Full Text]
Elliott, M. A., Mesa, R. A., Tefferi, A., Burton, C., Azzi, A., Kerridge, I. (2002). Adverse Events after Imatinib Mesylate Therapy. NEJM 346: 712-713 [Full Text]
Elmaagacli, A. H., Basoglu, S., Peceny, R., Trenschel, R., Ottinger, H., Lollert, A., Runde, V., Grosse-Wilde, H., Beelen, D. W., Schaefer, U. W. (2002). Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 99: 1130-1135 [Abstract] [Full Text]
Morley, J. E. (2002). Editorial: Drugs, Aging, and the Future. J. Gerontol. A Biol. Sci. Med. Sci. 57: M2-6 [Full Text]
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., Varmus, H. E. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15: 3249-3262 [Abstract] [Full Text]
(2001). A New Treatment for Chronic Myeloid Leukemia. JWatch General 2001: 8-8 [Full Text]

Comments and questions? Please contact us.